DexCom Cash Flow from Investing Activities 2010-2024 | DXCM
DexCom annual/quarterly cash flow from investing activities history and growth rate from 2010 to 2024. Cash flow from investing activities can be defined as the total change in cash resulting from a companies investments
- DexCom cash flow from investing activities for the quarter ending December 31, 2024 was $-0.208B, a 59.09% decline year-over-year.
- DexCom cash flow from investing activities for the twelve months ending December 31, 2024 was $-0.151B, a 93.61% decline year-over-year.
- DexCom annual cash flow from investing activities for 2024 was $-0.208B, a 59.09% decline from 2023.
- DexCom annual cash flow from investing activities for 2023 was $-0.507B, a 2.74% decline from 2022.
- DexCom annual cash flow from investing activities for 2022 was $-0.522B, a 141.32% increase from 2021.
| DexCom Annual Cash Flow Investing (Millions of US $) |
|
|---|---|
| 2024 | $-208 |
| 2023 | $-507 |
| 2022 | $-522 |
| 2021 | $-216 |
| 2020 | $-1,018 |
| 2019 | $-1,015 |
| 2018 | $-140 |
| 2017 | $-144 |
| 2016 | $-56 |
| 2015 | $-52 |
| 2014 | $-17 |
| 2013 | $21 |
| 2012 | $28 |
| 2011 | $-46 |
| 2010 | $-26 |
| 2009 | $-14 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | MED INSTRUMENTS | $32.004B | $4.033B |
| DexCom, Inc. is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems (CGM). These are for ambulatory use by people with diabetes and by healthcare providers for the treatment of diabetic and non-diabetic patients. A key element of DexCom's monitoring system technology is the continuous measure of patient's blood glucose level and transmission of that information to a small cell phone-sized receiver in real time. The company's monitoring systems aim to provide real-time continuous blood glucose values, trend data and alerts to assist patients in managing their blood glucose levels. | |||